LOS ANGELES, July 30, 2018 /PRNewswire/ -- CytRx Corporation
(Nasdaq: CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that it will
report financial results for the quarter ended June 30, 2018 on Monday,
August 6, 2018. CytRx executives Eric L. Curtis, President and Chief Operating
Officer, and John Caloz, Chief
Financial Officer, will hold a conference call and webcast
beginning at 11:00 a.m. Eastern Time
(8:00 a.m. Pacific Time) on that day
to discuss the financial results as well as provide an overview of
corporate achievements of both CytRx Corporation and Centurion
BioPharma Corporation.
To access the conference call, dial (+1)844-358-6753 (U.S.
and Canada) or (+1)216-562-0397 (international callers) and
enter the conference ID number: 5991089. A live and archived
webcast will be available in the News and Events/Events Calendar
section of the company's website, www.cytrx.com. A replay of
the call and webcast will begin approximately two hours after the
live call has ended. To access the replay, dial
(+1)855-859-2056 (U.S. and Canada) or (+1)404-537-3406
(international callers) and enter the conference ID number:
5991089.
About CytRx Corporation
CytRx Corporation (Nasdaq: CYTR) is a biopharmaceutical
company with expertise in discovering and developing new
therapeutics to treat patients with cancer. CytRx's most
advanced drug conjugate, aldoxorubicin, is an improved version of
the widely used anti-cancer drug doxorubicin and has been
out-licensed to NantCell, Inc. CytRx's website
is www.cytrx.com.
About Centurion BioPharma Corporation
CytRx's wholly owned subsidiary, Centurion BioPharma
Corporation, is focused on the development of personalized medicine
that will transform solid tumor treatment. This transformational
strategy combines a portfolio of novel, anti-cancer drug candidates
that employ LADR™ (Linker Activated Drug Release) technology, a
discovery engine designed to leverage Centurion's expertise in
albumin biology and linker technology for the development of a new
class of breakthrough anti-cancer therapies with a unique albumin
companion diagnostic (ACDx)™ that can help identify patients who
are most likely to benefit from treatment with the LADR™-derived
therapies. A critical element of the LADR™ platform is its ability
to bind anti-cancer molecules to circulating albumin, the most
ubiquitous protein in human blood plasma, and then to release the
highly potent cytotoxic payload at the tumor site. This technology
allows for the delivery of higher doses of drug directly to the
tumor, while avoiding much of the off-target toxicity observed with
the parent molecules. Centurion BioPharma's website is
www.centurionbiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to the ability of NantCell, Inc., to obtain
regulatory approval for its products that use aldoxorubicin; the
ability of NantCell, Inc., to manufacture and commercialize
products or therapies that use aldoxorubicin; the amount, if any,
of future milestone and royalty payments that we may receive from
NantCell, Inc.; Centurion BioPharma Corporation's ability to
develop new ultra-high potency drug candidates based on its LADR™
technology platform; our ability to attract potential licensees;
and other risks and uncertainties described in the most recent
annual and quarterly reports filed by CytRx with the Securities and
Exchange Commission and current reports filed since the date of
CytRx's most recent annual report. All forward-looking statements
are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
cytrx@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-to-hold-second-quarter-2018-financial-results-conference-call-and-webcast-on-monday-august-6-2018-300688217.html
SOURCE CytRx Corporation